<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005531'>Biphenotypic acute leukaemia</z:hpo> (BAL) represents about 5% of adult <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Based on a previously described scoring system, the European Group for Immunologic Classification of <z:mpath ids='MPATH_336'>Leukaemia</z:mpath> (EGIL) proposed a set of diagnostic criteria for BAL </plain></SENT>
<SENT sid="2" pm="."><plain>This scoring system is based on the number and degree of the specificity of several markers for myeloid or T/B lymphoid blasts </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we report the case of a BAL with Burkitt-like cytology, corresponding to "the <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, Burkitt type" L3 for the FAB classification </plain></SENT>
<SENT sid="4" pm="."><plain>By flow cytometry, the blasts showed a positivity for B lymphoid cytoplasmic (CD79a and mu) and membrane (CD19, CD22, CD24, IgM) markers AND a positivity for the myeloid (CD13, CD33, CD65, CD15) markers </plain></SENT>
</text></document>